Takara Bio USA, Inc. launches automated, full-length single-cell RNA-seq solution for enhanced biomarker discovery
San Jose, CA—October 18, 2021—Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the SMART-Seq Pro kit for the ICELL8 cx Single-Cell System. This automated single-cell RNA-seq solution allows scientists to generate full-length transcriptome data from over 1,500 single cells simultaneously and from a wide range of sample types—even large, delicate adult cardiomyocytes.
While single-cell RNA sequencing has exploded in popularity over the last 10 years, two significant challenges remain: maintaining the sensitivity of the assay during miniaturization and interrogating full-length mRNA transcripts for potential biomarkers. “Due to the limitations of most single-cell systems, scientists can only look for potential biomarkers at the ends of mRNA transcripts, and sensitivity is sacrificed for throughput," commented Carol Lou, President and CEO of Takara Bio USA. "Our new SMART-Seq Pro technology for the ICELL8 cx system, together with our bioinformatics tools, overcome these limitations, delivering full-length transcript information and enabling easy data analysis to power biomarker discovery."
The ICELL8 cx Single-Cell System is an advanced, integrated automation platform for imaging and dispensing thousands of single cells in 5,184-nanowell chips. With the launch of the SMART-Seq Pro kit for the ICELL8 cx system, Takara Bio USA has created an end-to-end solution for sensitive transcriptome analysis of up to eight samples at once. With the integrated Cogent Analysis Pipeline and Cogent Discovery software, scientists can analyze their samples for rare biomarkers like isoforms, gene fusions, and single nucleotide variants, which are missed with other systems.
Learn more by viewing data and other technical information.
Back to Blog Front
About Takara Bio
Takara Bio USA, Inc. (TBUSA) is a wholly owned subsidiary of Takara Bio Inc. that manufactures and distributes kits, reagents, and instruments for the life sciences, including NGS, PCR, gene delivery, genome editing, stem cell research, nucleic acid and protein purification, and automated sample preparation.
Takara Bio Inc., a world leader in biotechnology research and development, offers a host of life science research solutions, from enzymes and GMP-grade reagents to contracted cell and gene therapy manufacturing services and is the developer of the RetroNectin reagent, a world standard in gene therapy protocols. Takara Bio is committed to preventing disease and improving the quality of life for all people through the use of biotechnology.
Lorna Neilson, PhD
VP, Corporate Development
2560 Orchard Pkwy
San Jose, CA 95131
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2022 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.